The Manufacturers Life Insurance Company Buys New Holdings in Xenon Pharmaceuticals Inc. $XENE

The Manufacturers Life Insurance Company bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 28,932 shares of the biopharmaceutical company’s stock, valued at approximately $1,746,000.

Other institutional investors have also recently bought and sold shares of the company. Danske Bank A S bought a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at $32,000. Kestra Advisory Services LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at about $33,000. Osaic Holdings Inc. increased its stake in Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals in the fourth quarter worth about $43,000. Finally, Rockefeller Capital Management L.P. lifted its stake in Xenon Pharmaceuticals by 450.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 900 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. JPMorgan Chase & Co. raised their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Royal Bank Of Canada decreased their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Needham & Company LLC dropped their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, HC Wainwright restated a “buy” rating and issued a $74.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $77.13.

Insider Buying and Selling

In related news, Director Steven Gannon sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the completion of the transaction, the director owned 1,870 shares in the company, valued at $119,792.20. The trade was a 84.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christopher Kenney sold 7,068 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $60.25, for a total value of $425,847.00. Following the transaction, the insider directly owned 2 shares in the company, valued at approximately $120.50. This represents a 99.97% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ:XENE opened at $60.40 on Friday. The firm has a market cap of $5.84 billion, a P/E ratio of -12.74 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The company’s 50-day moving average price is $63.56 and its two-hundred day moving average price is $56.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the prior year, the company earned ($1.07) earnings per share. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.